Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe

By Northwest Biotherapeutics, PRNE
Tuesday, May 17, 2011

BETHESDA, Maryland, May 18, 2011 - Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that
it is partnering with Fraunhofer for production of DCVax(R)-L for brain
cancer, for clinical trials and compassionate use cases in Europe. Fraunhofer
is the largest applied research foundation in Europe, with a staff of more
than 18,000 scientists, engineers, business personnel and others dedicated to
practical applications and commercialization of research results, and with
annual operations in excess of euro 1.66 billion ($2.3 billion). Fraunhofer
is a highly respected leader in many areas of technology, including cell and
immune therapies.


The Fraunhofer Institute for Cell Therapy and Immunology IZI, based in
Leipzig, Germany, has dedicated a substantial portion of its state of the art
manufacturing facilities to the production of DCVax(R), and is assisting NWBT
with the applicable regulatory requirements for both clinical trials and
compassionate use cases. The Fraunhofer IZI is also selecting and initiating
connections with leading clinical centers on behalf of NWBT and its DCVax(R)

This partnering arrangement provides a solid foundation upon which NWBT
can proceed with clinical trials in Europe, and with compassionate use
treatments of patients in parallel with such clinical trials. In addition,
NWBT is eligible for certain grants through the German government which, if
approved, can amount to as much as euro 2 to 3 million ($2.8 to 4.2 million).

"Partnering with such a prestigious institution as the Fraunhofer IZI is
both gratifying and exciting," commented Dr. Alton Boynton, CEO of NWBT.
"This partnership can help accelerate the Company's brain cancer clinical
trials program, and also help save lives through compassionate use treatments
for other patients while the trials are ongoing."

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively than
current treatments, without toxicities of the kind associated with
chemotherapies, and on a cost-effective basis. The Company is developing
dendritic cell-based vaccines. The Company's lead clinical trial is a
240-patient Phase II trial in newly diagnosed Glioblastoma multiforme
("GBM"), the most aggressive and lethal form of brain cancer. The Company
also previously received clearance from the FDA for a 612-patient Phase III
trial in prostate cancer, and clearance from the FDA for Phase I trials in
five other cancers. The Company has also conducted a Phase I/II trial with
DCVax(R) for recurrent metastatic ovarian cancer. For further information
about clinical sites and about the Company, please visit the Company's web
site at

About the Fraunhofer Institute for Cell Therapy and Immunology

The Fraunhofer Institute for Cell Therapy and Immunology IZI is a member
of the Fraunhofer Group for Life Sciences. Its objective is to find solutions
to specific problems at the interfaces between medicine, life sciences and
engineering for partners active in medicine-related industries and
businesses. The Institute's core competencies are to be found in regenerative
medicine, or more precisely in cell-therapeutic methods of regenerating
non-functioning tissue and organs through to the biological substitution with
tissue cultivated in vitro (tissue engineering). In order for the living
organism to accept the tissues without any difficulty, it is necessary to
study cellular and immunological defense and control mechanisms and take
these into account during process and product development. These core
competencies entail a multiplicity of tasks to be solved by new products and
processes. The Institute works especially closely with hospital institutions,
performing quality tests and clinical studies on their behalf. Additionally
it also provides assistance in obtaining manufacturing licenses and


Statements made in this news release that are not historical facts,
including statements concerning future treatment of patients with GBM using
DCVax(R)-Brain and future clinical trials, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "expects," "believes," "intends," and similar expressions are
intended to identify forward-looking statements. Actual results may differ
materially from those projected in any forward-looking statement.
Specifically, there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the Company's
ability to raise additional capital, risks related to the Company's ability
to enroll patients in its clinical trials and complete the trials on a timely
basis, the uncertainty of the clinical trials process, uncertainties about
the timely performance of third parties, and whether the Company's products
will demonstrate safety and efficacy. Additional information on these and
other factors, including Risk Factors which could affect the Company's
results, are included in the Company's Securities and Exchange Commission
("SEC") filings. Finally, there may be other factors not mentioned above or
included in the Company's SEC filings that may cause actual results to differ
materially from those projected in any forward-looking statement. You should
not place undue reliance on any forward-looking statements. The Company
assumes no obligation to update any forward-looking statements as a result of
new information, future events or developments, except as required by
securities laws.

    Media contacts:
    NWBT:                   Fraunhofer:
    Dr. Alton Boynton       Dr. Gerno Schmiedeknecht     Mr. Jens Augustin
    +1-425-503-6351         +49-341-35536-9705           +49-341-35536-9320


Biotechnology News

May 18 News

will not be displayed